EUCTR2016-002902-37-CZ进行中（未招募）1 期
PROSPECTIVE, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE III STUDY EVALUATING EFFICACY AND SAFETY OF OCTAGAM 10% IN PATIENTS WITH DERMATOMYOSITIS - (ProDERM Study)
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 95
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Subjects with diagnosis of definite or probable DM according to the Bohan and Peter criteria.
- •2.Subjects under treatment with corticosteroids and/or maximally 2 immune-suppressants and being on stable therapy for at least 4 weeks (see Section 4.2.1) OR Subjects with previous failure of response or previous intolerance to corticosteroid and at least 1 additional immunosuppressive drug, and with steroid/immunosuppressive drugs ashed out as per Section 4.2.1 (Table 2).
- •3. Subjects with active disease, assessed and agreed upon by an independent adjudication committee. being on stable therapy for at least
- •4. Manual Muscle Testing-8 (MMT-8) score <142, with at least 2 other abnormal Core Set Measures (CSM) (Visual Analogue Scale [VAS] of patient global activity =2 cm, physician's global disease activity =2 cm, extra-muscular activity =2 cm; at least one muscle enzyme >1.5 times upper limit of normal, Health Assessment Questionnaire =0.25).
- •5. Males or females = 18 to < 80 years of age.
- •6. Voluntarily given, fully informed written consent obtained from subject before any study-related procedures are conducted.
- •7. Subject must be capable to understand and comply with the relevant aspects of the study protocol.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 84
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •1. Cancer-associated myositis, defined as the diagnosis of myositis
- •within 2 years of the diagnosis of cancer (except basal or squamous cell
- •skin cancer or carcinoma in situ of the cervix that has been excised and
- •cured and at least 1 or 5 years, respectively have passed since excision).
- •2. Evidence of active malignant disease or malignancies diagnosed
- •within the previous 5 years (including hematological malignancies and
- •solid tumors) or breast cancer diagnosed within the previous 10 years.
- •3. Subjects with overlap myositis (except for overlap with Sjögren's
- •syndrome), connective tissue disease associated DM, inclusion body
- •myositis, polymyositis, juvenile dermatomyositis or drug-induced
- •4. Subjects with immune-mediated necrotizing myopathy with absence
- •of typical DM rash.
- •5. Subjects with generalized, severe musculoskeletal conditions other
- •than DM that prevent a sufficient assessment of the subject by the
- •6. Subjects who have received IgG treatment within the last 6 months
- •before enrolment.
- •7. Subjects who received blood or plasma-derived products (other than
- •IgG) or plasma exchange within the last 3 months before enrolment.
- •8. Subjects starting or planning to start a physical therapy–directed
- •exercise regimen during the trial.
- •9. Cardiac insufficiency (New York Heart Association III/IV),
- •cardiomyopathy, significant cardiac dysrhythmia requiring treatment,
- •unstable or advanced ischemic heart disease.
- •10. Severe liver disease, with signs of ascites and hepatic
- •encephalopathy.
- •11. Severe kidney disease (as defined by estimated glomerular filtration
- •rate (eGFR) < 30 mL/min/1.73 m2).
- •12. Known hepatitis B, hepatitis C or HIV infection.
- •13. Subjects with a history of TEE such as deep vein thrombosis,
- •pulmonary embolism, myocardial infarction, ischemic stroke, transient
- •ischemic attack, peripheral artery disease (Fontaine IV) ever.
- •14. Body mass index =40 kg/m2.
- •15. Medical conditions whose symptoms and effects could alter protein
- •catabolism and/or IgG utilization (e.g. protein-losing enteropathies,
- •nephrotic syndrome).
- •16. Known IgA deficiency with antibodies to IgA.
- •17. History of hypersensitivity, anaphylaxis or severe systemic response
- •to immuno-globulin, blood or plasma derived products or any component
- •of Octagam 10%.
- •18. Known blood hyperviscosity, or other hypercoagulable states.
- •19. Subjects with a history of drug abuse within the past 5 years prior to
- •study enrollment.
- •20. Subjects unable or unwilling to understand or comply with the study
- •21. Participating in another interventional clinical study with
- •investigational treatment within 3 months prior to study enrollment.
- •22.Women who are breast feeding, pregnant, or planning to become
- •pregnant, or are unwilling to apply an effective birth control method
- •(such as implants, injectables, combined oral contraceptives, some
- •intrauterine devices [IUDs], sexual abstinence or vasectomized partner)
- •up to four weeks after the last IMP infusion.
- 另有 6 项未显示
研究者
相似试验
已完成
3 期
PROSPECTIVE, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE III STUDY EVALUATING EFFICACY AND SAFETY OF OCTAGAM 10% IN PATIENTS WITH DERMATOMYOSITIS1000381610028302DMDermatomyositisNL-OMON46776Octapharma Pharmazeutika Produktionsges m.b.H.6
进行中（未招募）
1 期
CLINICAL TRIAL TO EVALUATE EFFICACY AND SAFETY OF OCTAGAM 10% IN PATIENTS WITH DERMATOMYOSITIS (ProDERM Study)DermatomyositisEUCTR2016-002902-37-DEOctapharma Pharmazeutika Produktionsges.m.b.H.95
进行中（未招募）
1 期
CLINICAL TRIAL TO EVALUATE EFFICACY AND SAFETY OF OCTAGAM 10% IN PATIENTS WITH DERMATOMYOSITIS (ProDERM Study)MedDRA version: 20.0Level: LLTClassification code 10001403Term: Adult dermatomyositisSystem Organ Class: 100000004858DermatomyositisEUCTR2016-002902-37-NLOctapharma Pharmazeutika Produktionsges.m.b.H.95
进行中（未招募）
1 期
CLINICAL TRIAL TO EVALUATE EFFICACY AND SAFETY OF OCTAGAM 10% IN PATIENTS WITH DERMATOMYOSITIS (ProDERM Study)MedDRA version: 19.0Level: LLTClassification code 10001403Term: Adult dermatomyositisSystem Organ Class: 100000004858DermatomyositisEUCTR2016-002902-37-HUOctapharma Pharmazeutika Produktionsges.m.b.H.94
进行中（未招募）
不适用
PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF ERYTHROPOIETIN IN PATIENTS WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION UNDERGOING PERCUTANEOUS CORONARY INTERVENTION.REVIVAL-3 (Regeneration of Vital Myocardium in ST-Segment Elevation Myocardial Infarction by Erythropoietin) - REVIVAL-3EUCTR2006-003819-45-DEKlinik für Herz- und Kreislauferkrankungen, Deutsches Herzzentrum München